Document Detail

PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
MedLine Citation:
PMID:  25380967     Owner:  NLM     Status:  Publisher    
BACKGROUND: Cancer stem cells (CSC) represent a rare fraction of cancer cells characterized by resistance to chemotherapy and radiation, therefore nowadays there is great need to develop new targeted therapies for brain tumors and our study aim to target pivotal transmembrane receptors such as Notch, EGFR and PDGFR, which are already under investigation in clinical trials setting for the treatment of Glioblastoma Multiforme (GBM).
METHODS: MTS assay was performed to evaluate cells response to pharmacological treatments. Quantitative RT-PCR and Western blots were performed to state the expression of Notch1, EGFR and PDGFRalpha/beta and the biological effects exerted by either single or combined targeted therapy in GBM CSC. GBM CSC invasive ability was tested in vitro in absence or presence of Notch and/or EGFR signaling inhibitors.
RESULTS: In this study, we investigated gene expression and function of Notch1, EGFR and PDGFR to determine their role among GBM tumor core- (c-CSC) vs. peritumor tissue-derived cancer stem cells (p-CSC) of six cases of GBM. Notch inhibition significantly impaired cell growth of c-CSC compared to p-CSC pools, with no effects observed in cell cycle distribution, apoptosis and cell invasion assays. Instead, anti-EGFR therapy induced cell cycle arrest, sometimes associated with apoptosis and reduction of cell invasiveness in GBM CSC. In two cases, c-CSC pools were more sensitive to simultaneous anti-Notch and anti-EGFR treatment than either therapy alone compared to p-CSC, which were mostly resistant to treatment. We reported the overexpression of PDGFRalpha and its up-regulation following anti-EGFR therapy in GBM p-CSC compared to c-CSC. RNA interference of PDGFRalpha significantly reduced cell proliferation rate of p-CSC, while its pharmacological inhibition with Crenolanib impaired survival of both CSC pools, whose effects in combination with EGFR inhibition were maximized.
CONCLUSIONS: We have used different drugs combination to identify the more effective therapeutic targets for GBM CSC, particularly against GBM peritumor tissue-derived CSC, which are mostly resistant to treatments. Overall, our results provide the rationale for simultaneous targeting of EGFR and PDGFR, which would be beneficial in the treatment of GBM.
Carlo Cenciarelli; Hany Es Marei; Manuela Zonfrillo; Pasquale Pierimarchi; Emanuela Paldino; Patrizia Casalbore; Armando Felsani; Angelo Luigi Vescovi; Giulio Maira; Annunziato Mangiola
Related Documents :
20457897 - External and internal constraints on eukaryotic chemotaxis.
21317457 - Sumoylation of vimentin354 is associated with pias3 inhibition of glioma cell migration.
3934167 - Inhibition of cell-cell binding at the aggregation stage of dictyostelium discoideum de...
20052527 - Life and death in aluminium-exposed cultures of rat lactotrophs studied by flow cytometry.
24282057 - Association of tm4sf4 with the human thiamine transporter-2 in intestinal epithelial ce...
15205607 - Betulinic acid enhances 1alpha,25-dihydroxyvitamin d3-induced differentiation in human ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-8
Journal Detail:
Title:  Molecular cancer     Volume:  13     ISSN:  1476-4598     ISO Abbreviation:  Mol. Cancer     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-8     Completed Date:  -     Revised Date:  2014-11-9    
Medline Journal Info:
Nlm Unique ID:  101147698     Medline TA:  Mol Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  247     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early Results of Neurodevelopment Following Hybrid Stage I for Hypoplastic Left Heart Syndrome.
Next Document:  Assessment of risk of bias in controlled studies.